Celecoxib leads to G₂/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner

Hadas Dvory-Sobol, Efrat Cohen-Noymann, Diana Kazanou, Arie Figer, Shlomo Birkenfeld, Liora Madar-Shapiro, Robert Benamouzig, Nadir Arber

Article history:
Accepted 4 November 2005
Available online 19 January 2006

ARTICLE INFO
Keywords:
Colorectal cancer
Celecoxib
COX-2
Cell cycle
p53
p21

ABSTRACT
A unique in vitro system has been developed in our lab that consists of normal enterocytes derived from the rat ileum (IEC-18 cells) and their transformed derivatives with c-K-ras (R1 cells), anti-sense bak (B3 cells) and cyclin D1 (D1 cells). R1 and B3 cells express high level of COX-2 protein and PGE₂. IEC 18 and D1 cells express negligible amount of COX-2, and produce very low level of PGE₂. A relatively low dose of celecoxib (5-10 μM) induced G₂/M arrest, followed by induction of apoptosis in the transformed but not in the normal cells. Down-regulation of cyclin B1 and up-regulation of p21 expressions independent of p53 might have cause this cell cycle block. Growth inhibition was related to COX-2 function with 90-95% reduction in PGE₂ production. These findings may be of clinical importance, since low concentration of celecoxib can be achieved in human serum following standard anti-inflammatory (100-200 mg bid) regime.

1. Introduction
There are at least two isoforms of the cyclooxygenase (COX) enzyme. COX-1, a housekeeping protein, that is constitutively expressed in the normal gastrointestinal mucosa, while COX-2 is usually undetectable and its expression is induced by inflammatory and neoplastic stimuli. Up-regulated expression of COX-2 was observed in 40-50% of colorectal polyps and in up to 85% of colorectal cancer (CRC) [1]. The lack of COX-2 expression in the normal colonic mucosa, along with its increased expression in colonic neoplasm and the molecular differences between COX-1 and COX-2 constitute the rationale for the development of selective COX-2 inhibitors to prevent and treat colorectal tumours [2,3]. The direct cellular targets of COX-2 inhibitors responsible for their action are not completely understood and may involve several pathways resulting in the down-regulation of prostaglandin E₂ synthesis, inhibition of cell proliferation and angiogenesis, induction of apoptosis, cell cycle arrest and potentiation of the immune response (for reviews see [2,3]). Deregulation of normal cell cycle control has been implicated in the pathogenesis of most human cancers. In particular, abnormal expressions of regul-
latory proteins that control G1/S phase transition, a critical rate limiting step in cell cycle progression, are frequently observed. Celecoxib, a non steroid anti inflammatory drug (NSAID), is a specific inhibitor of COX-2, and was previously reported to induce G0/G1 arrest in many human cancer cells [4–6]. We have previously shown that celecoxib inhibits the growth of malignant but not normal cells [7].

In the current study, celecoxib, a specific COX-2 inhibitor selectively inhibited the growth of malignant cells by inducing a G0/M and not G0/G1 arrest as was previously reported. The growth inhibition was COX-2, but not p53, dependent. These findings might be of clinically importance, since low concentrations of celecoxib can be achieved in human serum.

2. Material and methods

2.1. Cells

The parental IEC-18 cells were normal rat enterocytes derived from rat ileum [8]. These cells were immortalized but non-tumorigenic and did not induce tumours in nude mice. R1 were IEC-18 cells transfected with pMlKcys that encoded a mini-human c-K-Ras gene (15 kb) with a cysteine mutation at codon 12 [8]. D1 cells were IEC-18 cells transfected with pMV7-D1, encoding the 1.1 kb human cyclin D1 cDNA [9]. B3 cells were IEC-18 cells transfected with human bak cDNA, cloned into the vector pMV12 in the anti-sense orientation (unpublished data). In contrast to the parental IEC-18 cells, transformed cells over-expressing K-ras, anti-sense bak and cyclin D1 proliferate faster, form colonies in soft agar, and have higher saturation density and plating efficiency. Most importantly, they form tumours when injected sub-cutaneously into nude mice [8,9]. Cells were exposed to celecoxib (5–20 μM) for 48–72 h. The control, untreated cells, received 1% of the drug vehicle DMSO.

2.2. Flow cytometry and cell cycle analysis

The measurement of DNA content using propidium iodide (PI) staining and flow cytometry was used to determine cell cycle distribution and apoptosis as previously described [7]. In brief, cells were plated at a density of 7 × 10^5/10 cm dish. Following drug exposure (5, 10 μM), 1–2 × 10^6 cells were collected, washed, fixed and stained with 45 μg/ml PI for 1 h before FACS analysis (necrotic cells were counted and eliminated using trypan blue staining before fixation). Data acquisition was performed on a FACS caliper and analyzed using CellQuest software (Becton Dickinson Immunocytometry Systems, San Jose, CA). The apoptotic cells were considered to constitute the sub-G1 population. All the experiments were performed independently at least three times, and the results were expressed as mean ± SD.

2.3. Reverse-transcriptase PCR (RT-PCR)

Total RNA was purified, following exposure to celecoxib (10 μM), using Nucleospin® RNA II Kit (Clontech, Palo Alto, California, USA) according to the manufacturer protocol. RT-PCR reaction was preformed, with 50 μg, on PTC-100 programmable thermal controller (MJ Research Inc, USA). Primers were designed using the LightCycler Primer Designer program (Roche Diagnostics, Mannheim, Germany) and were as follows:

- GAPDH (housekeeping gene): Forward, 5’-GGA GAT TGT TGC CAT CAA CG-3’; Reverse, 5’-TTG GTG GTG CAG GAT GCA TT-3’. p53: Forward, 5’-TTG CAG AGT TGT TAG AAG GC-3’; Reverse, 5’-GAA GAT TCC CAC TGG AGT CT-3’. PCR conditions were as follows: 2 min denaturation at 94 °C; each cycle consisting of 1 min at 94 °C, 1 min 56 °C, 1 min 15 s at 72 °C; and a final extension of 5 min at 72 °C. The PCR products were separated in 2% agarose/GelStar gel and visualized under UV light.

2.4. PGE2 synthesis measurement

Cells were exposed to celecoxib (10–20 μM) for 48–72 h. Released PGE2 in the medium was determined by a commercially available PGE2-specific enzyme-linked immunoassay (R&D biosystems, Abingdon, UK) according to the manufacturer’s protocol.

2.5. Cellular protein analysis

Exponentially growing cells were exposed to celecoxib (10 μM) for 48 h then collected and protein was extracted as previously described [7]. For western blotting, 50 μg of total cell lysate were loaded onto 12% SDS-polyacrylamide gel and subjected to electrophoresis. Proteins were transferred to Hybond-C membranes (Amersham, Arlington Heights, IL, USA). Membranes were treated with blocking solution (3% BSA in PBS 0.2% Tween-20) and incubated with various antibodies, including goat anti-actin (Santa Cruz Inc.), rabbit anti-p21 (Santa Cruz Inc.), mouse monoclonal anti-cyclin B1 (DAKO, Trappes, France) and mouse anti-p53 (NeoMrkers, Fermont, USA). Horseradish peroxidase-conjugated secondary antibody was used for immune detection using the ECL detection system (SuperSignal, Pierce, Rockford, USA). Densitometric quantification was performed using TINA 2.10 g program. Bands were normalized regarding actin levels.

3. Results

3.1. Effect on cell growth

The effect of increasing concentrations of celecoxib (up to 25 μM) for 72 h was assessed in IEC-18, R1, B3 and D1 cell lines (Fig. 1). Growth inhibition, in a dose dependent manner, was seen in R1 and B3 cells. No growth inhibition was seen in IEC-18 and D1 cell lines.

3.2. Celecoxib induces a G0/M arrest

Most of the IEC-18 cells were at G0/G1 stage, and their cell cycle was not altered by exposure to celecoxib. In contrast, growth inhibition in a dose-dependent manner in R1 and B3 cells was associated with G0/M arrest after 48 h exposure to the drug. After 72 h, the transformed cells entered apoptotic phase (Fig. 2). There was no effect on the growth of the transformed D1 cells that did not express COX-2.
3.3. The growth inhibition is independent of p53

IEC-18 and R1 cells harbouring p53 wild-type gene [10] had abundant p53 mRNA (Fig. 3). At the same time, p53 protein was not detected in the transformed cells even after exposure to celecoxib (10 μM) (data not shown). Hence, the growth inhibition in the transformed cells, seen in this model, was p53 independent. It is suggested that mutated K-ras has an important role on the cell cycle, and eliminated p53 activity by translation inhibition or induction of its degradation.

3.4. Celecoxib induces p21 and down regulate cyclin B1 expression

It has been previously described that p21 induces cell cycles arrest by both p53-dependent and independent pathways [11]. Western blot analysis demonstrated a two-fold decrease in the expression of cyclin B1 and two-fold increase of p21 in R1 and B3 cells as compared to IEC-18 and D1 cells, following celecoxib treatment (10 μM) (Fig. 4). These results were confirmed by immunofluorescence methods (data not shown).

3.5. Growth inhibition is COX-2 dependent and is associated with inhibition of PGE2 synthesis

In order to ascertain if the drug effects were dependent on COX-2, we used tumourigenic cells (R1 and B3) that had high COX-2 activity and expressed high levels of PGE2, in contrast to the parental IEC-18 cells that have negligible COX-2 activity and very low level of PGE2. Treatment with celecoxib (5–20 μM) for 48–72 h inhibited more than 95% of PGE2 production (Fig. 5), suggesting that the action of celecoxib, in this model, is PGE2 dependent. Furthermore, the growth of transformed D1 cells, that did not express COX-2, was not inhibited and there was no change in their cell cycle. Also in D1 cells, celecoxib did not induce apoptosis even at high doses of the drug (20 μM) (Fig. 2).

4. Discussion

In this study, celecoxib inhibited the growth of transformed cells expressing COX-2 protein (R1 and B3 cells), but not that of normal cells or transformed cells that did not express COX-2 (D1 cells). It confirmed our previous observations that celecoxib inhibits the growth of malignant cells only [7].

Most of the IEC-18 cells were in G0/G1 phase, and their cell cycle was not altered by exposure to celecoxib. Celecoxib inhibited cell growth by induction of apoptosis, even following exposure to low concentrations of the drug (5 μM). At the same time, no effect was seen in the parental IEC-18 cells, nor in transformed cells (D1) expressing low level of COX-2.

This is the first report describing that celecoxib can also induce G2/M arrest in transformed intestinal epithelial cells over-expressing COX-2 (R1 and B3), before directing the cells into the apoptotic phase.

The findings are intriguing as previous reports suggested that celecoxib causes a G0/G1 block [4–6,12]. The different results presented here might be due to different dosing; relatively low doses (5–20 μM) in the current study as compared to higher concentrations (25–100 μM) in the other studies. Similar findings of G2/M block was reported by Ding [13]. However, their findings were obtained in oral cancer cells and followed exposure to significantly higher dose (50 μM) of celecoxib, that are not clinically achievable. There is only one study that has used similar low dose (5 μM) of celecoxib, that are not clinically achievable. There is only one study that has used similar low dose (5 μM) of celecoxib [14], and they demonstrated that very low (5 μM) clinically achievable concentrations of celecoxib inhibited the growth of prostate cancer cells, that lacked COX-2, by induction of G2/M block. It might be that celecoxib inhibits cell growth differently in different organs (intestine versus prostate). The G2/ M block induced in this study, was achieved in numerous re-
At the same time, cellular transport of cyclin B1 as well [19], IEC-18, R1 and B3 cells harbour G2/M transitions. This effect gets do exist in the intestine, COX-2 is an important target of celecoxib. Therefore, growth inhibition in the transformed cells seen in this model was p53 independent. The finding that p53 does not appear to play a role in the growth-inhibitory effects of celecoxib is not surprising, as numerous papers have demonstrated that celecoxib has growth-inhibitory effects in almost all cell lines investigated, whether or not these cells harbor wild-type or mutant p53. It was previously described that p21 induces cell cycle arrest by both p53-dependent and independent pathways [11]. As a proliferation inhibitor, p21 is poised to play an important role in preventing tumour development. Up-regulation of p21 along with down-regulation of cyclin B1 in R1 and B3 cells, following celecoxib treatment, can promote G2/M arrest and induction of apoptosis in a p53-independent pathway.

It is well known that celecoxib inhibits tumor growth in both COX-2 dependent and independent manners [2,20]. Treatment with celecoxib inhibited more than 95% of PGE2 production in tumourigenic cells that had high COX-2 activity, suggesting that the action of celecoxib in this model is PGE2-dependent. Furthermore, growth of the transformed D1 cells, that did not express COX-2, was not inhibited; apoptosis was not induced; and there was no change in their cell cycle even at fairly high dose of celecoxib. These observations further support the notion, that although numerous non COX-2 targets do exist in the intestine, COX-2 is an important target of celecoxib.

In summary, celecoxib inhibits cell growth by inducing a G2/M arrest followed by induction of apoptosis. Increased p21 levels and down-regulation of cyclin B1 expression may be the underlying mechanism for this G2/M arrest. This effect is COX-2 dependent and p53 independent. These results are clinically important since the drug concentration used can be achieved in human serum following standard anti-inflammatory (100–200 mg ) and anti-neoplastic (400–800 mg) regimens range between 3.9–8 µM [21,22]. These novel effects of celecoxib provide new insights into the molecular mechanisms responsible for the anti-tumour effects of this compound, and may encourage further application of this and related compounds in the prevention and treatment of COX-2 expressors cells.
Conflict of interest statement

None declared.

Acknowledgement

Funding from the Israel Cancer Association and Pfizer Inc. (to NA) supported this study. This work was part of the requirements of Hadas Dvory-Sobol for her PhD degree, and Efrat Cohen-Noyman for her MSc degree at the Sackler School of Medicine at Tel Aviv University, Israel.

REFERENCES